Hospital-treated Gram-negative Infections Market Gains Momentum During Forecast Period 2026

By Author: DBMR
Total Articles: 177
Comment this article

Market Analysis: Global Hospital-Treated Gram-Negative Infections Market
Hospital-treated gram-negative infections market is expected to register a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the continuous research and development of various pharmaceutical organizations.
Global Hospital-Treated Gram-Negative Infections Market By Therapy (Cephalosporin, Aminoglycoside; Ampicillin/Sulbactam, Carbapenem, Colistin or Rifampin; Aminoglycoside, Carbapenem, Colistin, Fosfomycin, Rifampin, or Tigecycline; Ceftolozane/Tazobactam; Ceftazidime/Avibactam; Others); Indication (NP; cSSSIs/SSIs; BSIs; cIAIs; UTIs); Pathogen Type (Klebsiella; Acinetobacter; Coli; Cepacia; Pseudomonas; Serratia; Enterobacter; Others); Application (Hospitals; Labs); Geography (North America; Europe; Asia-Pacific; South America; Middle East and Africa) – Industry Trends and Forecast to 2026
Get Sample Report@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hospital-treated-gram-negative-infections-market
...
... Market Definition: Global Hospital-Treated Gram-Negative Infections Market
Hospital-treated gram-negative infections are microbial infections caused by different pathogens interacting with the patient’s bloodstream through wounds, surgical sites and other areas in a healthcare setting. These infections are caused by various pathogens with the most common, “klebsiella”, “E.coli”, “Acinetobacter” and various others.
Patients suffering from gram negative infections are known to have high fever, lack of appetite, nausea and in some extreme cases even seizures. Their treatment and removal is achieved with the help of combination of different therapeutics and systems inclusive of regular controlled dosage of anti-microbials with anti-biotics.
Market Drivers
· Increasing rate and prevalence of antibiotic resistance is expected to boost the growth of the market
· Lack of effectiveness in treating of these anti-microbial infections with the help of traditional therapeutics is expected to boost the growth of the market
· Growing mortality rate caused by anti-microbial resistance is giving rise to better therapeutic solutions; this factor is expected to drive the growth of the market
Market Restraints
· Lack in the availability of anti-microbial agents in the form of pharmaceuticals or drug pipeline for the treatment of gram-negative infections; this factor is expected to restrict the growth of the market
· Significant numbers of resistance and challenges facing the companies and pharmaceuticals regarding the development of treatment solutions; this factor is expected to restrict the growth of the market
Get Detailed Report@ https://www.databridgemarketresearch.com/reports/global-hospital-treated-gram-negative-infections-market
Competitive Analysis:
Global hospital-treated gram-negative infections market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hospital-treated gram-negative infections market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Competitors:
Few of the major competitors currently working in the global hospital-treated gram-negative infections market are Merck & Co., Inc.; Pfizer Inc.; Lupin Pharmaceuticals, Inc.; Istituto Lusofarmaco D'Italia S.p.A.; Adelco; Achaogen, Inc.; ALLERGAN; MELINTA THERAPEUTICS, INC.; Polyphor Ltd.; Shionogi Inc.; Tetraphase Pharmaceuticals; Spero Therapeutics; AiCuris GmbH & Co. KG; Allecra Therapeutics; SUMMIT THERAPEUTICS PLC; Curza; Boston Pharmaceuticals and Nabriva Therapeutics plc among others.
Get Access Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-hospital-treated-gram-negative-infections-market
Research Methodology: Global Hospital-Treated Gram-Negative Infections Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hospital-treated-gram-negative-infections-market
Key Developments in the Market:
· In June 2019, MELINTA THERAPEUTICS, INC. announced that the US FDA had accepted the company’s supplemental NDA (sNDA) for “BAXDELA (delafloxacin)” for priority review. The application will expand the current indication application for adults with community-acquired bacterial pneumonia (CABP). This approval is based on positive results out of Phase III study
· In October 2018, Novartis AG announced that they had agreed with Boston Pharmaceuticals for the development of anti-infective drug candidates included in “Novartis Infectious Diseases” portfolio. These candidates will be designed for treatment of anti-biotic resistance such as “gram-negative infections”. This agreement will provide Boston Pharmaceuticals worldwide rights, wherein Novartis will receive financial payments upfront as well as in royalties and milestone achievements
Related Trending Reports @
· Dermatology Treatment Devices Market
· Companion Diagnostics Market
· Sepsis Diagnostics Market
· Heart Pump Devices Market
· Transradial Access Market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com